Skip to content

Research Project on the Prevention and Control of Clonorchiasis (Subproject 1: Comparative Study on the Therapeutic Efficacy of Anthelmintic Drugs against Clonorchiasis)

Research Project on the Prevention and Control of Clonorchiasis (Subproject 1: Comparative Study on the Therapeutic Efficacy of Anthelmintic Drugs against Clonorchiasis)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115406
Enrollment
Unknown
Registered
2025-12-25
Start date
2025-09-25
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clonorchiasis

Interventions

Tribendimidine Group:Tribendimidine: 0.4 g once daily (qd) for 3 days.
Albendazole Group:Albendazole: 10 mg/kg once daily (qd) for 7 days.
Praziquantel Group:Praziquantel: 25 mg/kg, three times a day (tid) for 2 days

Sponsors

The People’s Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older, regardless of gender. 2. Conform to the definitive diagnosis of clonorchiasis as per the latest editions of Infectious Diseases and the Expert Consensus on the Diagnosis and Treatment of Foodborne Parasitic Diseases (2023), confirmed by the presence of eggs or adult worms in stool examination or bile drainage fluid. 3. Patient agrees to the study plan and provides written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a known allergy or hypersensitivity to albendazole, praziquantel, or tribendimidine. 2. Patients with severe hepatic, renal, or cardiac insufficiency, or active ulcer disease. 3. Patients with a confirmed diagnosis of concurrent cerebral cysticercosis by clinical or imaging examination; 4. Patients with a confirmed diagnosis of concurrent ocular cysticercosis by clinical or imaging examination. 5. Patients with gallstones or biliary tract obstruction as indicated by abdominal ultrasonography. 6. Pregnant or lactating women, and women who are planning a pregnancy. 7. Patients who are planning to relocate, refuse to continue participation, or are unable to complete the protocol-defined follow-up for any other reason.

Design outcomes

Primary

MeasureTime frame
Re-examination of stool for Clonorchis sinensis eggs and calculation of the egg reduction rate;

Secondary

MeasureTime frame
Hematological parameters (complete blood count, liver function biochemical tests).;Hepatobiliary ultrasound (to assess for findings indicative of clonorchiasis infection, etc.).;

Countries

China

Contacts

Public ContactZhang Li

The People’s Hospital of Guangxi Zhuang Autonomous Region

30173359@qq.com+86 771 2186165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026